Nama Insights

Veracyte (VCYT)

Healthcare · Diagnostics Research · NASDAQ

Veracyte (VCYT) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $2.02B, a trailing price-to-earnings ratio of 11.9 and a free-cash-flow yield of 6.3%. Over the most recent reported fiscal year, revenue grew 16.0% and free cash flow per share grew 92.5%. Nama's AI scorecard rates it Buy, 7.2 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 7.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Momentum
Middle · +13.2% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-58.7%
How far the last close sits under the highest price of the past five years.
Market cap$2.02B
Trailing P/E11.9
Price / book1.4
Price / sales3.5
FCF yield6.3%
Dividend yield—
Gross margin72.0%
Operating margin17.6%
Net margin21.8%
Revenue growth (YoY)+16.0%
Revenue growth (3-yr annual)+20.4%
EPS growth (YoY)+73.8%
FCF/share growth (YoY)+92.5%
Beta2.0
ExchangeNASDAQ
SectorHealthcare
IndustryDiagnostics Research

VCYT earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.38). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 4, 2026 $0.51 $0.41 +24.4% $151.75M
Q2 2026 Jul 30, 2026 $0.54 $0.43 +25.6% $150.32M
Q1 2026 May 5, 2026 $0.52 $0.33 +57.6% $139.07M
Q4 2025 Feb 25, 2026 $0.53 $0.41 +29.3% $140.64M

VCYT analyst price target

Median target $40.00 from 10 analysts, ranging $30.00 – $60.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $255.19B 27.9
DHR Danaher $160.10B 27.3
WAT Waters $89.71B 31.7
IDXX IDEXX Laboratories $54.33B 46.5
A Agilent Technologies $49.44B 28.9
NTRA Natera $42.04B —
IQV IQVIA $41.29B 19.6
MTD Mettler-Toledo International $33.93B 36.8
Explore live VCYT data on Nama Insights →

Recent Congressional trades

Veracyte trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Gilbert Cisneros House Buy $1,001 - $15,000 Apr 7, 2026
Gilbert Cisneros House Sell $1,001 - $15,000 Dec 15, 2025
Gilbert Cisneros House Buy $1,001 - $15,000 Jul 10, 2025
Josh Gottheimer House Buy $1,001 - $15,000 Nov 11, 2023
Josh Gottheimer House Sell $1,001 - $15,000 Oct 15, 2023

VCYT FAQ

Is VCYT a buy?
Nama's AI scorecard currently rates Veracyte Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VCYT's P/E ratio?
Veracyte trades at a trailing price-to-earnings ratio of 11.9.
When does VCYT report earnings?
Veracyte's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.38.
What is the VCYT price target?
The median analyst price target from 10 analysts is $40.00, with a range of $30.00 – $60.00.
Is VCYT Shariah compliant?
Nama's AAOIFI-style screen reads Veracyte as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.